ClinicalTrials.gg
CompletedNCT05080764Updated Oct 1, 2026Results posted

Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Moderate to Severe Acne Vulgaris With Photodynamic Therapy in Adults

A Phase 2 interventional study of 1h Incubation Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT) and 1h Incubation Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient) in Acne Vulgaris, sponsored by Biofrontera Inc.. Completed at 9 sites in United States. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Biofrontera Inc. · Phase 2, Interventional, and Treatment

How we know

Updated Oct 1, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 374 studies in Acne Vulgaris with a site in United States — 20 open to participants now, 29 under way, 2 of them phase 3. Acne Vulgaris · United States.

Enrollment
158th of 354
120 · median 78
Started
2021
with 14 others
Phase 2
65 of 374
none open now
Registered
308th of 374
by date

Among the 374 studies in Acne Vulgaris with a site in United States, this one is the 158th largest by enrollment of the 354 interventional ones that give a count, is one of 15 that started in 2021, is one of 65 in phase 2, and was the 308th registered.

Acne Vulgaris

795 studies on the registry are indexed under Acne Vulgaris; 96 are open to participants now.

Browse Acne Vulgaris studies →

Open to participants now

20 of the 374 studies in Acne Vulgaris with a site in United States are open now. Recruiting first, the newest first:

15 more — sign in →

All 20 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 48 Acne Vulgaris studies recruiting now, 17 (35%) set no upper age limit and 30 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 374 studies in Acne Vulgaris with a site in United States, or all of them as a file.
02

Study summary

The aim of this study is to test the safety and efficacy of photodynamic therapy (PDT) for the medication Ameluz® performed with the PDT-lamp BF-RhodoLED® in comparison to the respective placebo treatment for moderate to severe Acne vulgaris.

03

Conditions studied

  • Acne Vulgaris

Browse trials for

Keywords

  • ALA-PDT
04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Willingness and ability of the subject to provide and to sign the Health Insurance Portability and Accountability Act (HIPAA) form. A study-specific informed consent and HIPAA form must be obtained in writing prior to starting any study procedures. Minors under 18 years of age must be accompanied by the parent(s) or legal guardian(s) at the time of consent signing. The parent(s) or legal guardian(s) must also provide informed consent/HIPAA for the subject.
  2. Subjects with moderate to severe acne on the face (IGA ≥3).
  3. Presence of ≥20 inflammatory and ≥20 non-inflammatory (open and closed comedones) Acne vulgaris lesions on the face (should be located within not more than 2 illumination areas) as assessed by investigator.
  4. All sexes, ≥16 years of age.
  5. Willingness and ability to comply with study procedures, particularly willingness to receive up to 3 PDTs within 8 to 10 weeks.
  6. Subjects with good general health or with clinically stable medical conditions will be permitted to be included in the study.
  7. Willingness to stop topical facial treatments other than medical cleansers (i.e. face washes etc.) at least 14 days prior to randomization visit (Visit 2, baseline) and discontinue medical cleansers in the face at least 1 week prior to randomization visit (Visit 2, baseline) and thereafter until the end of study (use of soap is allowed but the product used should not be changed during the study).
  8. Females of must have a negative serum pregnancy test and must use an adequate and highly effective or two effective methods of throughout the study. (If hormonal contraception is used, the same product and dose should be taken for at least 6 months before the first treatment and throughout the entire study.)

Exclusion criteria

Exclusion Criteria:

  1. Any known history of to ALA, porphyrins or of BF-200 ALA.
  2. History of soy or peanut allergy.
  3. Subjects with sunburn or other possible confounding skin conditions (e.g. wounds, irritations, bleeding or skin infections) within or in close proximity (\< 5 cm distance) to treatment field. (Reassessment of subjects is allowed once if the sunburn or other confounding skin conditions is/are expected to resolve within the screening period.

    Reassessment can be done on the day of the actual treatment.)

  4. Clinical diagnosis of atopic dermatitis and other cutaneous conditions (e.g. lupus erythematosus), Bowen's disease, BCC, eczema, psoriasis, acne conglobate, acne fulminans, or secondary acne (-induced acne, perioral dermatitis, acne rosacea), squamous cell carcinoma, other malignant or benign tumors in the treatment field.
  5. (CS) medical conditions making implementation of the protocol or interpretation of the study results difficult or impairing subject's safety such as:

    1. Presence of photodermatoses or porphyria
    2. tumor or tumor with high probability of metastasis
    3. Infiltrating skin neoplasia (suspected or known)
    4. Unstable cardiovascular disease ( class III, IV)
    5. Unstable hematologic (including Myelodysplastic syndrome), hepatic, renal, neurologic, or endocrine condition
    6. Unstable collagen-vascular condition
    7. Unstable gastrointestinal condition
    8. condition
    9. Presence of clinically significant inherited or acquired coagulation defect
  6. Beard or other facial hair that might interfere with the study assessments unless subject agrees to be clean-shaven throughout the entire study period. (Reassessment of subjects is allowed once if assessment of acne lesions is impaired by facial hair at screening. Reassessment can be performed on the day of the actual treatment).
  7. Facial procedures such as dermabrasion, chemical or laser peels as well as exposure to UV radiation (other than sunlight) at least 4 weeks prior to randomization visit (Visit 2, baseline).
  8. Presence of strong artificial pigmentation (e.g. tattoos) or any other abnormality that may impact lesion assessment or light penetration in the treatment field.
  9. Suspicion of drug or alcohol abuse.
  10. Any topical medication of the skin prior to screening as defined below:

    1. Topical treatment with ALA or ALA-esters (e.g. MAL) or an drug in- and outside the treatment field within 8 weeks prior to screening.
    2. Topical treatment with immunosuppressive, cytostatic or cytotoxic drugs inside the treatment field within 8 weeks prior to screening.
    3. Start of a regular and continuous topical administration of medication with hypericin or other drugs with phototoxic or photoallergic potential inside the treatment field within 4 weeks prior to screening. Subjects may, however, be eligible if such medication was regularly applied for more than 4 weeks prior to screening visit without evidence of an actual phototoxic/photoallergic reaction or if such medication is only administered for a limited time (e.g. an antibiotic)
  11. Any use of the below specified systemic treatments within the designated periods:

    1. Systemic acne therapy (oral antibiotics within 8 weeks or oral isotretinoin within 6 months or start with hormonal therapy for acne within 6 months prior to Visit 2).
    2. Use of cytotoxic or cytostatic drugs within 6 months, or immunosuppressive therapies or use of ALA or ALA-esters (e.g. MAL) within 12 weeks, investigational drugs or drugs known to have major organ toxicity within 8 weeks, interferon or glycocorticosteroids (oral or injectable) within 6 weeks prior to screening.
    3. Start of long-term intake of medication with hypericin or systemically acting drugs with phototoxic or photoallergic potential within 8 weeks prior to screening. Subjects may, however, be screened and randomized if such medication was taken in or was regularly applied for more than 8 weeks prior to screening visit without evidence of an actual phototoxic/photoallergic reaction or if such a drug is only used for a limited time (e.g. an antibiotic).
  12. Breast feeding women.
  13. Subject unlikely to comply with protocol, e.g. inability to return for visits, unlikely to complete the study, or inappropriate in the opinion of the investigator.
  14. Prior randomization in the study.
  15. A member of study site staff or sponsor staff directly involved in the conduct of the protocol or a close relative thereof.
  16. Simultaneous participation in a further clinical study.
  17. Four or more nodular acne lesions on the face.
  18. Unwillingness or inability to limit sun exposure for 48 hours post PDT treatment.

Dosing Day exclusion criteria:

  1. Febrile or infectious disease within 7 days prior to PDT visits.
  2. Subjects with sunburn, wounds, irritations, bleeding or other confounding skin conditions within illumination areas at PDT visits.
  3. Application of topical glycocorticosteroids in- and outside the treatment field within 7 days prior to PDT visits
  4. Administration of (topical or systemic) medication with phototoxic/photoallergic potential for a limited time. After discontinuing the medication, a wash out period of the medications 5-fold half-life time should be applied prior to the next PDT.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
120 participants (actual)

Study arms

  • Experimental
    1h incubation BF-200 ALA

    Topical application of BF-200 ALA containing 7.8% 5-ALA (5-aminolevulinic acid) red light photodynamic therapy (PDT) utilizing BF-RhodoLED® after 1h incubation.

    Combination Product: 1h Incubation Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT)

  • Experimental
    3h incubation BF-200 ALA

    Topical application of BF-200 ALA containing 7.8% 5-ALA (5-aminolevulinic acid) red light photodynamic therapy (PDT) utilizing BF-RhodoLED® after 3h incubation.

    Combination Product: 3h Incubation Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT)

  • Placebo comparator
    1h incubation vehicle

    Topical application of vehicle to BF-200 ALA red light photodynamic therapy (PDT) utilizing BF-RhodoLED® after 1h incubation.

    Combination Product: 1h Incubation Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient)

  • Placebo comparator
    3h incubation vehicle

    Topical application of vehicle to BF-200 ALA red light photodynamic therapy (PDT) utilizing BF-RhodoLED® after 3h incubation.

    Combination Product: 3h Incubation Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient)

Interventions

  • Combination product1h Incubation Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT)

    The treatment field (whole face excluding the periocular area) will be cleansed with gauze soaked with ethanol or isopropanol. Afterwards, approximately 1 tube of study medication will be applied as a thin layer. After drug application, subjects should stay inside for 1 hour. Post incubation, red light illumination with BF-RhodoLED® will be performed according to the lamps user manual until a total light energy of 37 J/cm2 was applied. To cover the whole face 2 illuminations will be required which can either be performed subsequentially or in parallel (with 2 lamps). Other Names: ALA-PDT, Ameluz®-PDT

  • Combination product1h Incubation Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient)

    The treatment field (whole face excluding the periocular area) will be cleansed with gauze soaked with ethanol or isopropanol. Afterwards, approximately 1 tube of study medication will be applied as a thin layer. After drug application, subjects should stay inside for 1h. Post incubation, red light illumination with BF-RhodoLED® will be performed according to the lamps user manual until a total light energy of 37 J/cm2 was applied. To cover the whole face 2 illuminations will be required which can either be performed subsequentially or in parallel (with 2 lamps).

  • Combination product3h Incubation Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT)

    The treatment field (whole face excluding the periocular area) will be cleansed with gauze soaked with ethanol or isopropanol. Afterwards, approximately 1 tube of study medication will be applied as a thin layer. After drug application, subjects should stay inside for 3 hours. Post incubation, red light illumination with BF-RhodoLED® will be performed according to the lamps user manual until a total light energy of 37 J/cm2 was applied. To cover the whole face 2 illuminations will be required which can either be performed subsequentially or in parallel (with 2 lamps). Other Names: ALA-PDT, Ameluz®-PDT

  • Combination product3h Incubation Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient)

    The treatment field (whole face excluding the periocular area) will be cleansed with gauze soaked with ethanol or isopropanol. Afterwards, approximately 1 tube of study medication will be applied as a thin layer. After drug application, subjects should stay inside for 3h. Post incubation, red light illumination with BF-RhodoLED® will be performed according to the lamps user manual until a total light energy of 37 J/cm2 was applied. To cover the whole face 2 illuminations will be required which can either be performed subsequentially or in parallel (with 2 lamps).

06

What researchers measure

Primary outcomes

  1. Relative Change in the Number of Inflammatory Lesions (Relative Change From Baseline) 8 Weeks After the Last PDT as Assessed by Investigator.

    Outcome 1 is the relative change in the number of inflammatory lesions at the final visit with respect to baseline as assessed by the investigator.

    Time frame: 8 weeks after the last PDT

  2. Treatment Success Defined by a Minimum Improvement of the Modified Investigator Global Assessment (mIGA) Score by at Least 2 Assessed 8 Weeks After the Last PDT and Resulting in an mIGA Score of 0 (Clear) or 1 (Almost Clear).

    Treatment success is defined as a minimum improvement of the mIGA score by at least 2 and resulting in an mIGA score of 0 (clear) or 1 (almost clear).

    Time frame: 8 weeks after the last PDT

Secondary outcomes

  1. Absolute Change From Baseline in the Number of Lesions as Assessed by Investigator (After the Last PDT).

    In particular, the following will be assessed: 1. Inflammatory lesions - 4 weeks after the last PDT 2. Inflammatory lesions - 8 weeks after the last PDT 3. Non-inflammatory lesions - 4 weeks after the last PDT 4. Non-inflammatory lesions - 8 weeks after the last PDT 5. Inflammatory \& non-inflammatory lesions - 4 weeks after the last PDT 6. Inflammatory \& non-inflammatory lesions - 8 weeks after the last PDT

    Time frame: 4 or 8 weeks after the last PDT

  2. Percentage Change From Baseline in the Number of Lesions as Assessed by Investigator (After the Last PDT).

    In particular, the following will be assessed: 1. Inflammatory lesions - 4 weeks after the last PDT 2. Inflammatory lesions - 8 weeks after the last PDT 3. Non-inflammatory lesions - 4 weeks after the last PDT 4. Non-inflammatory lesions - 8 weeks after the last PDT 5. Inflammatory \& non-inflammatory lesions - 4 weeks after the last PDT 6. Inflammatory \& non-inflammatory lesions - 8 weeks after the last PDT

    Time frame: 4 or 8 weeks after the last PDT

  3. Absolute Change From Baseline in the Number of Lesions as Assessed by Investigator (After Each PDT).

    In particular, the following will be assessed: 1. Inflammatory lesions - 4 weeks after PDT-1 2. Non-inflammatory lesions - 4 weeks after PDT-1 3. Inflammatory and non-inflammatory lesions - 4 weeks after PDT-1 4. Inflammatory lesions - 4 weeks after PDT-2 5. Non-inflammatory lesions - 4 weeks after PDT-2 6. Inflammatory and non-inflammatory lesions - 4 weeks after PDT-2 7. Inflammatory lesions - 4 weeks after PDT-3 8. Non-inflammatory lesions - 4 weeks after PDT-3 9. Inflammatory and non-inflammatory lesions - 4 weeks after PDT-3 10. Inflammatory lesions - 8 weeks after PDT-3 11. Non-inflammatory lesions - 8 weeks after PDT-3 12. Inflammatory and non-inflammatory lesions - 8 weeks after PDT-3

    Time frame: 4 or 8 weeks after the last PDT

  4. Percentage Change From Baseline in the Number of Lesions as Assessed by Investigator (After Each PDT).

    In particular, the following will be assessed: 1. Inflammatory lesions - 4 weeks after PDT-1 2. Non-inflammatory lesions - 4 weeks after PDT-1 3. Inflammatory and non-inflammatory lesions - 4 weeks after PDT-1 4. Inflammatory lesions - 4 weeks after PDT-2 5. Non-inflammatory lesions - 4 weeks after PDT-2 6. Inflammatory and non-inflammatory lesions - 4 weeks after PDT-2 7. Inflammatory lesions - 4 weeks after PDT-3 8. Non-inflammatory lesions - 4 weeks after PDT-3 9. Inflammatory and non-inflammatory lesions - 4 weeks after PDT-3 10. Inflammatory lesions - 8 weeks after PDT-3 11. Non-inflammatory lesions - 8 weeks after PDT-3 12. Inflammatory and non-inflammatory lesions - 8 weeks after PDT-3

    Time frame: 4 or 8 weeks after the last PDT

  5. Absolute Change From Baseline in the Number of Lesions as Assessed by Investigator, Only for Responders at Visit 3 / 4 Weeks After PDT-1.

    In particular, the following will be assessed: 1. Inflammatory lesions - 4 weeks after PDT-1 2. Inflammatory lesions - 8 weeks after PDT-1 3. Non-Inflammatory lesions - 4 weeks after PDT-1 4. Non-Inflammatory lesions - 8 weeks after PDT-1 5. Inflammatory \& non-inflammatory lesions - 4 weeks after PDT-1 6. Inflammatory \& non-inflammatory lesions - 8 weeks after PDT-1

    Time frame: 4 or 8 weeks after PDT-1

  6. Percentage Change From Baseline in the Number of Lesions as Assessed by Investigator, Only for Responders at Visit 3 / 4 Weeks After PDT-1.

    In particular, the following will be assessed: 1. Inflammatory lesions - 4 weeks after PDT-1 2. Inflammatory lesions - 8 weeks after PDT-1 3. Non-Inflammatory lesions - 4 weeks after PDT-1 4. Non-Inflammatory lesions - 8 weeks after PDT-1 5. Inflammatory \& non-inflammatory lesions - 4 weeks after PDT-1 6. Inflammatory \& non-inflammatory lesions - 8 weeks after PDT-1

    Time frame: 4 or 8 weeks after PDT-1

  7. Absolute Change From Baseline in the Number of Lesions as Assessed by Investigator, Only for Responders at Visit 4b / 4 Weeks After PDT-2.

    In particular, the following will be assessed: 1. Inflammatory lesions - 4 weeks after PDT-2 2. Inflammatory lesions - 8 weeks after PDT-2 3. Non-Inflammatory lesions - 4 weeks after PDT-2 4. Non-Inflammatory lesions - 8 weeks after PDT-2 5. Inflammatory \& non-inflammatory lesions - 4 weeks after PDT-2 6. Inflammatory \& non-inflammatory lesions - 8 weeks after PDT-2

    Time frame: 4 or 8 weeks after PDT-2

  8. Percentage Change From Baseline in the Number of Lesions as Assessed by Investigator, Only for Responders at Visit 4b / 4 Weeks After PDT-2.

    In particular, the following will be assessed: 1. Inflammatory lesions - 4 weeks after PDT-2 2. Inflammatory lesions - 8 weeks after PDT-2 3. Non-Inflammatory lesions - 4 weeks after PDT-2 4. Non-Inflammatory lesions - 8 weeks after PDT-2 5. Inflammatory \& non-inflammatory lesions - 4 weeks after PDT-2 6. Inflammatory \& non-inflammatory lesions - 8 weeks after PDT-2

    Time frame: 4 or 8 weeks after PDT-2

  9. Absolute Change in the Number of Lesions as Assessed by Investigator, Only for Responders at Visit 5b / 4 Weeks After PDT-3.

    In particular, the following be assessed: 1. Inflammatory lesions - 4 weeks after PDT-3 2. Inflammatory lesions - 8 weeks after PDT-3 3. Non-Inflammatory lesions - 4 weeks after PDT-3 4. Non-Inflammatory lesions - 8 weeks after PDT-3 5. Inflammatory \& non-inflammatory lesions - 4 weeks after PDT-3 6. Inflammatory \& non-inflammatory lesions - 8 weeks after PDT-3

    Time frame: 4 or 8 weeks after PDT-3

  10. Percentage Change in the Number of Lesions as Assessed by Investigator, Only for Responders at Visit 5b / 4 Weeks After PDT-3.

    In particular, the following be assessed: 1. Inflammatory lesions - 4 weeks after PDT-3 2. Inflammatory lesions - 8 weeks after PDT-3 3. Non-Inflammatory lesions - 4 weeks after PDT-3 4. Non-Inflammatory lesions - 8 weeks after PDT-3 5. Inflammatory \& non-inflammatory lesions - 4 weeks after PDT-3 6. Inflammatory \& non-inflammatory lesions - 8 weeks after PDT-3

    Time frame: 4 or 8 weeks after PDT-3

  11. Absolute Change in the Number of Nodules & Cysts

    The number of nodules and cysts was assessed by investigator.

    Time frame: 8 weeks after the last PDT

  12. Percentage Change in the Number of Nodules & Cysts

    The number of nodules and cysts was assessed by investigator. Percentage change from baseline was calculated only for participants whose number of nodules and cysts had changed at 8 weeks after the last PDT.

    Time frame: 8 weeks after the last PDT

  13. Treatment Success Defined by a Minimum Improvement of the IGA by at Least 2.

    Treatment success is defined as a minimum improvement of the IGA score by at least 2 (from baseline (Visit 2) as assessed by investigator).

    Time frame: 8 weeks after the last PDT

  14. Improvement of the IGA.

    As assessed by the investigator.

    Time frame: 8 weeks after the last PDT

  15. Improvement of the mIGA.

    As assessed by the investigator.

    Time frame: 8 weeks after the last PDT

  16. Improvement of Scar Severity and Overall Esthetic Appearance.

    Improvement of scar severity: As assessed by the investigator via a physical global scale for acne scars (PGA). Overall esthetic appearance: As assessed by the investigator using a 4-point scale (0= very good, 1 = good, 2 = satisfactory, 3 = unsatisfactory)

    Time frame: 8 weeks after last PDT

  17. Satisfaction Regarding Esthetic Outcome and Treatment.

    As reported by the subject. Subject's Satisfaction with PDT (No = No, I would not choose this treatment again; Yes = Yes, I would choose this treatment again) Assessment of Esthetic Outcome (0=Very good, 1=Good, 2=Satisfactory, 3=Unsatisfactory)

    Time frame: 8 weeks after the last PDT.

Other outcomes

  1. Frequency and Severity of Adverse Events (AEs), Serious AEs (SAEs), AEs of Special Interest (AESI) and Treatment-emerged Adverse Events (TEAEs).

    TEAEs are defined as all AEs with onset on or after first treatment with randomized IMP up to study termination of the subject.

    Time frame: from screening to study completion, over a duration of up to approximately 25 weeks

  2. Application Site Skin Reaction Assessed by Investigator

    Only local skin reactions with an onset during illumination are included here. Events occurring during the illumination period (10 minutes) at PDT-1, PDT-2, and PDT-3 were counted at each occurrence and summed across all three time points. Application site skin reactions were recorded and analyzed as TEAEs and are also described in the "Adverse Events" section.

    Time frame: During illumination (10 minutes) at PDT-1, PDT-2, and PDT-3

  3. Application Site Discomfort Reported by the Subjects.

    Only local skin discomforts with an onset during illumination are included here. Events occurring during the illumination period (10 minutes) at PDT-1, PDT-2, and PDT-3 were counted at each occurrence and summed across all three time points. Application site skin reactions were recorded and analyzed as TEAEs and are also described in the "Adverse Events" section.

    Time frame: During illumination (10 minutes) at PDT-1, PDT-2, and PDT-3

  4. Pain During Illumination Reported by the Subject.

    Subject's pain intensity during illumination is assessed at the end of illumination period using a numeric rating pain scale ranging from no pain at all (0) to worst possible pain (10). The maximum of pain score over across both illumination areas for PDT-1, PDT-2 and PDT-3 is shown.

    Time frame: During illumination (10 minutes) at PDT-1, PDT-2, and PDT-3

  5. Changes in Blood Pressure

    Number of patients with changes in blood pressure (systolic and diastolic) \[mmHg\]. Findings which differed from reference range and were considered clinically significant were to be reported.

    Time frame: at all clinic visits conducted over a duration of approximately 25 weeks

  6. Changes in Heart Rate

    Number of patients with changes in heart rate \[beats/min\]. Findings which differed from reference range and were considered clinically significant were to be reported.

    Time frame: at all clinic visits conducted over a duration of approximately 25 weeks

  7. Investigation of Clinical Chemistry Parameters

    Findings which differ from reference range and are considered to be clinically significant are to be reported.

    Time frame: first and last visit conducted up to approximately 25 weeks apart

  8. Investigation of Hematology Parameters

    Number of patients with changes in hematology parameters. Findings which differed from reference range and were considered clinically significant were to be reported.

    Time frame: first and last visit conducted up to approximately 25 weeks apart

  9. Investigation of Urinalysis Parameters

    Number of patients with changes in urinalysis parameters. Findings which differed from reference range and were considered clinically significant were to be reported.

    Time frame: first and last visit conducted up to approximately 25 weeks apart

  10. Physical Examination of Head, Neck, Skin, Lymph Nodes, Thorax Including Heart and Lungs, Abdomen, and Musculoskeletal, Peripheral Vascular and Nervous System Status

    Physical examination of head, neck, skin, lymph nodes, thorax including heart and lungs, abdomen, and musculoskeletal, peripheral vascular and nervous system status were to be performed. Abnormal findings considered clinically significant were to be reported.

    Time frame: first and last visit conducted up to approximately 25 weeks apart

07

Results

Posted Oct 1, 2026

Participant flow

Participant flow — Overall Study
Milestone1h Incubation BF-200 ALA3h Incubation BF-200 ALA1h Incubation Vehicle3h Incubation Vehicle
Started42362121
Completed29211514
Not completed131567
Withdrew: Adverse event2111
Withdrew: Lost to follow-up5230
Withdrew: Sponsor request1101
Withdrew: Withdrawal by subject2614
Withdrew: Physician decision0100
Withdrew: Forbidden medication2410
Withdrew: Subject decision0001
Withdrew: Joint decision of subject and investigator1000

Outcome measures

PrimaryRelative Change in the Number of Inflammatory Lesions (Relative Change From Baseline) 8 Weeks After the Last PDT as Assessed by Investigator.

Outcome 1 is the relative change in the number of inflammatory lesions at the final visit with respect to baseline as assessed by the investigator.

Time frame:
8 weeks after the last PDT
Reported as:
Mean · percentage change from baseline
Relative Change in the Number of Inflammatory Lesions (Relative Change From Baseline) 8 Weeks After the Last PDT as Assessed by Investigator.
percentage change from baseline1h Incubation BF-200 ALA3h Incubation BF-200 ALAVehicle (1h and 3h Incubation Pooled)
Relative Change in the Number of Inflammatory Lesions (Relative Change From Baseline) 8 Weeks After the Last PDT as Assessed by Investigator.-37.89 ± 39.92-48.69 ± 31.75-38.84 ± 41.84
PrimaryTreatment Success Defined by a Minimum Improvement of the Modified Investigator Global Assessment (mIGA) Score by at Least 2 Assessed 8 Weeks After the Last PDT and Resulting in an mIGA Score of 0 (Clear) or 1 (Almost Clear).

Treatment success is defined as a minimum improvement of the mIGA score by at least 2 and resulting in an mIGA score of 0 (clear) or 1 (almost clear).

Time frame:
8 weeks after the last PDT
Reported as:
Count of participants · Participants
Treatment Success Defined by a Minimum Improvement of the Modified Investigator Global Assessment (mIGA) Score by at Least 2 Assessed 8 Weeks After the Last PDT and Resulting in an mIGA Score of 0 (Clear) or 1 (Almost Clear).
Participants1h Incubation BF-200 ALA3h Incubation BF-200 ALAVehicle (1h and 3h Incubation Pooled)
Treatment Success Defined by a Minimum Improvement of the Modified Investigator Global Assessment (mIGA) Score by at Least 2 Assessed 8 Weeks After the Last PDT and Resulting in an mIGA Score of 0 (Clear) or 1 (Almost Clear).578
SecondaryAbsolute Change From Baseline in the Number of Lesions as Assessed by Investigator (After the Last PDT).

In particular, the following will be assessed: 1. Inflammatory lesions - 4 weeks after the last PDT 2. Inflammatory lesions - 8 weeks after the last PDT 3. Non-inflammatory lesions - 4 weeks after the last PDT 4. Non-inflammatory lesions - 8 weeks after the last PDT 5. Inflammatory \& non-inflammatory lesions - 4 weeks after the last PDT 6. Inflammatory \& non-inflammatory lesions - 8 weeks after the last PDT

Time frame:
4 or 8 weeks after the last PDT
Reported as:
Mean · lesions
Absolute Change From Baseline in the Number of Lesions as Assessed by Investigator (After the Last PDT).
lesions1h Incubation BF-200 ALA3h Incubation BF-200 ALAVehicle (1h and 3h Incubation Pooled)
a. Inflammatory lesions - 4 weeks after the last PDT-9.0 ± 12.8-18.9 ± 13.4-15.2 ± 21.7
b. Inflammatory lesions - 8 weeks after the last PDT-7.3 ± 11.6-19.6 ± 14.3-15.4 ± 23.1
c. Non-inflammatory lesions - 4 weeks after the last PDT-5.6 ± 24.7-18.2 ± 29.6-16.3 ± 27.0
d. Non-inflammatory lesions - 8 weeks after the last PDT-8.6 ± 15.4-22.8 ± 27.8-16.7 ± 28.6
e. Infl. & non-inflammatory lesions - 4 weeks after the last PDT-14.6 ± 32.1-37.1 ± 33.5-31.5 ± 45.0
f. Infl. & non-inflammatory lesions - 8 weeks after the last PDT-16.0 ± 22.0-42.4 ± 31.9-32.0 ± 48.1
SecondaryPercentage Change From Baseline in the Number of Lesions as Assessed by Investigator (After the Last PDT).

In particular, the following will be assessed: 1. Inflammatory lesions - 4 weeks after the last PDT 2. Inflammatory lesions - 8 weeks after the last PDT 3. Non-inflammatory lesions - 4 weeks after the last PDT 4. Non-inflammatory lesions - 8 weeks after the last PDT 5. Inflammatory \& non-inflammatory lesions - 4 weeks after the last PDT 6. Inflammatory \& non-inflammatory lesions - 8 weeks after the last PDT

Time frame:
4 or 8 weeks after the last PDT
Reported as:
Mean · percentage
Percentage Change From Baseline in the Number of Lesions as Assessed by Investigator (After the Last PDT).
percentage1h Incubation BF-200 ALA3h Incubation BF-200 ALAVehicle (1h and 3h Incubation Pooled)
a. Inflammatory lesions - 4 weeks after the last PDT-37.92 ± 45.09-55.24 ± 28.04-44.05 ± 41.12
b. Inflammatory lesions - 8 weeks after the last PDT-31.99 ± 43.16-58.98 ± 26.74-43.68 ± 40.61
c. Non-inflammatory lesions - 4 weeks after the last PDT-18.70 ± 61.88-36.60 ± 40.00-42.27 ± 39.71
d. Non-inflammatory lesions - 8 weeks after the last PDT-28.35 ± 38.80-46.36 ± 41.97-42.23 ± 40.13
e. Infl. & non-inflammatory lesions - 4 weeks after the last PDT-28.13 ± 46.20-45.82 ± 30.57-43.63 ± 36.25
f. Infl. & non-inflammatory lesions - 8 weeks after the last PDT-29.68 ± 36.25-54.04 ± 29.45-42.09 ± 36.31
SecondaryAbsolute Change From Baseline in the Number of Lesions as Assessed by Investigator (After Each PDT).

In particular, the following will be assessed: 1. Inflammatory lesions - 4 weeks after PDT-1 2. Non-inflammatory lesions - 4 weeks after PDT-1 3. Inflammatory and non-inflammatory lesions - 4 weeks after PDT-1 4. Inflammatory lesions - 4 weeks after PDT-2 5. Non-inflammatory lesions - 4 weeks after PDT-2 6. Inflammatory and non-inflammatory lesions - 4 weeks after PDT-2 7. Inflammatory lesions - 4 weeks after PDT-3 8. Non-inflammatory lesions - 4 weeks after PDT-3 9. Inflammatory and non-inflammatory lesions - 4 weeks after PDT-3 10. Inflammatory lesions - 8 weeks after PDT-3 11. Non-inflammatory lesions - 8 weeks after PDT-3 12. Inflammatory and non-inflammatory lesions - 8 weeks after PDT-3

Time frame:
4 or 8 weeks after the last PDT
Reported as:
Mean · lesions
Absolute Change From Baseline in the Number of Lesions as Assessed by Investigator (After Each PDT).
lesions1h Incubation BF-200 ALA3h Incubation BF-200 ALAVehicle (1h and 3h Incubation Pooled)
a. Inflammatory lesions - 4 weeks after PDT-1-6.8 ± 7.6-9.4 ± 10.9-9.4 ± 14.5
b. Non-inflammatory lesions - 4 weeks after PDT-1-4.1 ± 15.8-15.0 ± 18.3-11.8 ± 14.7
c. Inflammatory and non-inflammatory lesions - 4 weeks after PDT-1-10.9 ± 17.4-24.4 ± 23.0-21.2 ± 27.2
d. Inflammatory lesions - 4 weeks after PDT-2-9.3 ± 13.9-17.2 ± 14.4-15.2 ± 19.7
e. Non-inflammatory lesions - 4 weeks after PDT-2-5.4 ± 17.4-20.0 ± 28.9-17.7 ± 24.7
f. Inflammatory and non-inflammatory lesions - 4 weeks after PDT-2-14.7 ± 21.8-37.2 ± 32.3-32.8 ± 41.3
g. Inflammatory lesions - 4 weeks after PDT-3-8.8 ± 13.0-19.8 ± 12.9-16.6 ± 21.5
h. Non-inflammatory lesions - 4 weeks after PDT-3-3.7 ± 22.6-19.2 ± 29.9-18.3 ± 26.8
i. Inflammatory and non-inflammatory lesions - 4 weeks after PDT-3-12.5 ± 30.3-39.0 ± 32.9-34.8 ± 44.4
j. Inflammatory lesions - 8 weeks after PDT-3-7.3 ± 11.6-19.6 ± 14.3-15.4 ± 23.1
k. Non-inflammatory lesions - 8 weeks after PDT-3-8.6 ± 15.4-22.8 ± 27.8-16.7 ± 28.6
l. Inflammatory and non-inflammatory lesions - 8 weeks after PDT-3-16.0 ± 22.0-42.4 ± 31.9-32.0 ± 48.1
SecondaryPercentage Change From Baseline in the Number of Lesions as Assessed by Investigator (After Each PDT).

In particular, the following will be assessed: 1. Inflammatory lesions - 4 weeks after PDT-1 2. Non-inflammatory lesions - 4 weeks after PDT-1 3. Inflammatory and non-inflammatory lesions - 4 weeks after PDT-1 4. Inflammatory lesions - 4 weeks after PDT-2 5. Non-inflammatory lesions - 4 weeks after PDT-2 6. Inflammatory and non-inflammatory lesions - 4 weeks after PDT-2 7. Inflammatory lesions - 4 weeks after PDT-3 8. Non-inflammatory lesions - 4 weeks after PDT-3 9. Inflammatory and non-inflammatory lesions - 4 weeks after PDT-3 10. Inflammatory lesions - 8 weeks after PDT-3 11. Non-inflammatory lesions - 8 weeks after PDT-3 12. Inflammatory and non-inflammatory lesions - 8 weeks after PDT-3

Time frame:
4 or 8 weeks after the last PDT
Reported as:
Mean · percentage
Percentage Change From Baseline in the Number of Lesions as Assessed by Investigator (After Each PDT).
percentage1h Incubation BF-200 ALA3h Incubation BF-200 ALAVehicle (1h and 3h Incubation Pooled)
a. Inflammatory lesions - 4 weeks after PDT-1-26.02 ± 27.26-34.72 ± 33.34-30.65 ± 34.55
b. Non-inflammatory lesions - 4 weeks after PDT-1-11.40 ± 45.48-31.89 ± 29.92-33.13 ± 34.53
c. Inflammatory and non-inflammatory lesions - 4 weeks after PDT-1-20.01 ± 27.18-32.28 ± 27.14-31.71 ± 29.18
d. Inflammatory lesions - 4 weeks after PDT-2-36.49 ± 49.95-50.87 ± 25.76-44.66 ± 32.24
e. Non-inflammatory lesions - 4 weeks after PDT-2-16.83 ± 45.60-39.34 ± 37.22-47.18 ± 30.81
f. Inflammatory and non-inflammatory lesions - 4 weeks after PDT-2-27.21 ± 33.57-45.25 ± 25.73-45.04 ± 25.75
g. Inflammatory lesions - 4 weeks after PDT-3-37.36 ± 45.72-58.14 ± 24.90-48.58 ± 35.99
h. Non-inflammatory lesions - 4 weeks after PDT-3-16.73 ± 61.86-39.09 ± 39.08-48.09 ± 33.52
i. Inflammatory and non-inflammatory lesions - 4 weeks after PDT-3-26.66 ± 46.19-48.51 ± 28.36-48.68 ± 30.50
j. Inflammatory lesions - 8 weeks after PDT-3-31.99 ± 43.16-58.98 ± 26.74-43.68 ± 40.61
k. Non-inflammatory lesions - 8 weeks after PDT-3-28.35 ± 38.80-46.36 ± 41.97-42.23 ± 40.13
l. Inflammatory and non-inflammatory lesions - 8 weeks after PDT-3-29.68 ± 36.25-54.04 ± 29.45-42.09 ± 36.31
SecondaryAbsolute Change From Baseline in the Number of Lesions as Assessed by Investigator, Only for Responders at Visit 3 / 4 Weeks After PDT-1.

In particular, the following will be assessed: 1. Inflammatory lesions - 4 weeks after PDT-1 2. Inflammatory lesions - 8 weeks after PDT-1 3. Non-Inflammatory lesions - 4 weeks after PDT-1 4. Non-Inflammatory lesions - 8 weeks after PDT-1 5. Inflammatory \& non-inflammatory lesions - 4 weeks after PDT-1 6. Inflammatory \& non-inflammatory lesions - 8 weeks after PDT-1

Time frame:
4 or 8 weeks after PDT-1
Reported as:
Mean · lesions

No measurements were reported for this outcome.

SecondaryPercentage Change From Baseline in the Number of Lesions as Assessed by Investigator, Only for Responders at Visit 3 / 4 Weeks After PDT-1.

In particular, the following will be assessed: 1. Inflammatory lesions - 4 weeks after PDT-1 2. Inflammatory lesions - 8 weeks after PDT-1 3. Non-Inflammatory lesions - 4 weeks after PDT-1 4. Non-Inflammatory lesions - 8 weeks after PDT-1 5. Inflammatory \& non-inflammatory lesions - 4 weeks after PDT-1 6. Inflammatory \& non-inflammatory lesions - 8 weeks after PDT-1

Time frame:
4 or 8 weeks after PDT-1
Reported as:
Mean · percentage

No measurements were reported for this outcome.

SecondaryAbsolute Change From Baseline in the Number of Lesions as Assessed by Investigator, Only for Responders at Visit 4b / 4 Weeks After PDT-2.

In particular, the following will be assessed: 1. Inflammatory lesions - 4 weeks after PDT-2 2. Inflammatory lesions - 8 weeks after PDT-2 3. Non-Inflammatory lesions - 4 weeks after PDT-2 4. Non-Inflammatory lesions - 8 weeks after PDT-2 5. Inflammatory \& non-inflammatory lesions - 4 weeks after PDT-2 6. Inflammatory \& non-inflammatory lesions - 8 weeks after PDT-2

Time frame:
4 or 8 weeks after PDT-2
Reported as:
Mean · lesions

No measurements were reported for this outcome.

SecondaryPercentage Change From Baseline in the Number of Lesions as Assessed by Investigator, Only for Responders at Visit 4b / 4 Weeks After PDT-2.

In particular, the following will be assessed: 1. Inflammatory lesions - 4 weeks after PDT-2 2. Inflammatory lesions - 8 weeks after PDT-2 3. Non-Inflammatory lesions - 4 weeks after PDT-2 4. Non-Inflammatory lesions - 8 weeks after PDT-2 5. Inflammatory \& non-inflammatory lesions - 4 weeks after PDT-2 6. Inflammatory \& non-inflammatory lesions - 8 weeks after PDT-2

Time frame:
4 or 8 weeks after PDT-2
Reported as:
Mean · percentage

No measurements were reported for this outcome.

SecondaryAbsolute Change in the Number of Lesions as Assessed by Investigator, Only for Responders at Visit 5b / 4 Weeks After PDT-3.

In particular, the following be assessed: 1. Inflammatory lesions - 4 weeks after PDT-3 2. Inflammatory lesions - 8 weeks after PDT-3 3. Non-Inflammatory lesions - 4 weeks after PDT-3 4. Non-Inflammatory lesions - 8 weeks after PDT-3 5. Inflammatory \& non-inflammatory lesions - 4 weeks after PDT-3 6. Inflammatory \& non-inflammatory lesions - 8 weeks after PDT-3

Time frame:
4 or 8 weeks after PDT-3
Reported as:
Mean · lesions
Absolute Change in the Number of Lesions as Assessed by Investigator, Only for Responders at Visit 5b / 4 Weeks After PDT-3.
lesions1h Incubation BF-200 ALA3h Incubation BF-200 ALAVehicle (1h and 3h Incubation Pooled)
a. Inflammatory lesions - 4 weeks after PDT-3—-21 ± 0—
b. Inflammatory lesions - 8 weeks after PDT-3—-21 ± 0—
c. Non-Inflammatory lesions - 4 weeks after PDT-3—1 ± 0—
d. Non-Inflammatory lesions - 8 weeks after PDT-3—-22 ± 0—
e. Inflammatory & non-inflammatory lesions - 4 weeks after PDT-3—-20 ± 0—
f. Inflammatory & non-inflammatory lesions - 8 weeks after PDT-3—-43 ± 0—
SecondaryPercentage Change in the Number of Lesions as Assessed by Investigator, Only for Responders at Visit 5b / 4 Weeks After PDT-3.

In particular, the following be assessed: 1. Inflammatory lesions - 4 weeks after PDT-3 2. Inflammatory lesions - 8 weeks after PDT-3 3. Non-Inflammatory lesions - 4 weeks after PDT-3 4. Non-Inflammatory lesions - 8 weeks after PDT-3 5. Inflammatory \& non-inflammatory lesions - 4 weeks after PDT-3 6. Inflammatory \& non-inflammatory lesions - 8 weeks after PDT-3

Time frame:
4 or 8 weeks after PDT-3
Reported as:
Mean · percentage
Percentage Change in the Number of Lesions as Assessed by Investigator, Only for Responders at Visit 5b / 4 Weeks After PDT-3.
percentage1h Incubation BF-200 ALA3h Incubation BF-200 ALAVehicle (1h and 3h Incubation Pooled)
a. Inflammatory lesions - 4 weeks after PDT-3—-100 ± 0—
b. Inflammatory lesions - 8 weeks after PDT-3—-100 ± 0—
c. Non-Inflammatory lesions - 4 weeks after PDT-3—4.17 ± 0—
d. Non-Inflammatory lesions - 8 weeks after PDT-3—-91.67 ± 0—
e. Inflammatory & non-inflammatory lesions - 4 weeks after PDT-3—-44.44 ± 0—
f. Inflammatory & non-inflammatory lesions - 8 weeks after PDT-3—-95.56 ± 0—
SecondaryAbsolute Change in the Number of Nodules & Cysts

The number of nodules and cysts was assessed by investigator.

Time frame:
8 weeks after the last PDT
Reported as:
Mean · lesions
Absolute Change in the Number of Nodules & Cysts
lesions1h Incubation BF-200 ALA3h Incubation BF-200 ALAVehicle (1h and 3h Incubation Pooled)
Nodules-0.2 ± 1.3-0.1 ± 1.1-0.2 ± 1.0
Cysts0 ± 1.00 ± 0.4-0.2 ± 0.6
Other pre-specifiedFrequency and Severity of Adverse Events (AEs), Serious AEs (SAEs), AEs of Special Interest (AESI) and Treatment-emerged Adverse Events (TEAEs).

TEAEs are defined as all AEs with onset on or after first treatment with randomized IMP up to study termination of the subject.

Time frame:
from screening to study completion, over a duration of up to approximately 25 weeks
Reported as:
Count of participants · Participants
Frequency and Severity of Adverse Events (AEs), Serious AEs (SAEs), AEs of Special Interest (AESI) and Treatment-emerged Adverse Events (TEAEs).
Participants1h Incubation BF-200 ALA3h Incubation BF-200 ALAVehicle (1h and 3h Incubation Pooled)
AEs403531
SAEs011
AESIs000
TEAEs403531
Any TEAE related to IMP and/or IMD403527
Any TEAE related to IMP and/or IMD, mild383326
Any TEAE related to IMP and/or IMD, moderate242410
Any TEAE related to IMP and/or IMD, severe6112
Other pre-specifiedApplication Site Skin Reaction Assessed by Investigator

Only local skin reactions with an onset during illumination are included here. Events occurring during the illumination period (10 minutes) at PDT-1, PDT-2, and PDT-3 were counted at each occurrence and summed across all three time points. Application site skin reactions were recorded and analyzed as TEAEs and are also described in the "Adverse Events" section.

Time frame:
During illumination (10 minutes) at PDT-1, PDT-2, and PDT-3
Reported as:
Count of participants · Participants
Application Site Skin Reaction Assessed by Investigator
Participants1h Incubation BF-200 ALA3h Incubation BF-200 ALAVehicle (1h and 3h Incubation Pooled)
Application Site Skin Reaction Assessed by Investigator482
Other pre-specifiedApplication Site Discomfort Reported by the Subjects.

Only local skin discomforts with an onset during illumination are included here. Events occurring during the illumination period (10 minutes) at PDT-1, PDT-2, and PDT-3 were counted at each occurrence and summed across all three time points. Application site skin reactions were recorded and analyzed as TEAEs and are also described in the "Adverse Events" section.

Time frame:
During illumination (10 minutes) at PDT-1, PDT-2, and PDT-3
Reported as:
Count of participants · Participants
Application Site Discomfort Reported by the Subjects.
Participants1h Incubation BF-200 ALA3h Incubation BF-200 ALAVehicle (1h and 3h Incubation Pooled)
Application Site Discomfort Reported by the Subjects.383121
Other pre-specifiedPain During Illumination Reported by the Subject.

Subject's pain intensity during illumination is assessed at the end of illumination period using a numeric rating pain scale ranging from no pain at all (0) to worst possible pain (10). The maximum of pain score over across both illumination areas for PDT-1, PDT-2 and PDT-3 is shown.

Time frame:
During illumination (10 minutes) at PDT-1, PDT-2, and PDT-3
Reported as:
Mean · pain score
Pain During Illumination Reported by the Subject.
pain score1h Incubation BF-200 ALA3h Incubation BF-200 ALAVehicle (1h and 3h Incubation Pooled)
PDT-12.3 ± 2.33.4 ± 3.00.7 ± 1.4
PDT-22.5 ± 2.23.8 ± 3.20.5 ± 0.9
PDT-32.0 ± 2.23.7 ± 2.90.6 ± 1.7
Other pre-specifiedChanges in Blood Pressure

Number of patients with changes in blood pressure (systolic and diastolic) \[mmHg\]. Findings which differed from reference range and were considered clinically significant were to be reported.

Time frame:
at all clinic visits conducted over a duration of approximately 25 weeks
Reported as:
Count of participants · Participants
Changes in Blood Pressure
Participants1h Incubation BF-200 ALA3h Incubation BF-200 ALAVehicle (1h and 3h Incubation Pooled)
Screening000
Baseline/PDT-1000
4 weeks post PDT-1/PDT-2000
4 weeks post PDT-2/PDT-3000
4 weeks post PDT-3000
8 weeks post PDT-3000
Other pre-specifiedChanges in Heart Rate

Number of patients with changes in heart rate \[beats/min\]. Findings which differed from reference range and were considered clinically significant were to be reported.

Time frame:
at all clinic visits conducted over a duration of approximately 25 weeks
Reported as:
Count of participants · Participants
Changes in Heart Rate
Participants1h Incubation BF-200 ALA3h Incubation BF-200 ALAVehicle (1h and 3h Incubation Pooled)
Screening000
Baseline/PDT-1000
4 weeks post PDT-1/PDT-2000
4 weeks post PDT-2/PDT-3000
4 weeks post PDT-3000
8 weeks post PDT-3000
Other pre-specifiedInvestigation of Clinical Chemistry Parameters

Findings which differ from reference range and are considered to be clinically significant are to be reported.

Time frame:
first and last visit conducted up to approximately 25 weeks apart
Reported as:
Count of participants · Participants
Investigation of Clinical Chemistry Parameters
Participants1h Incubation BF-200 ALA3h Incubation BF-200 ALAVehicle (1h and 3h Incubation Pooled)
Screening — No clinically significant clinical chemistry parameters reported403235
Screening — Clinically significant clinical chemistry parameters reported101
8 weeks post PDT-3 — No clinically significant clinical chemistry parameters reported261926
8 weeks post PDT-3 — Clinically significant clinical chemistry parameters reported100
Other pre-specifiedInvestigation of Hematology Parameters

Number of patients with changes in hematology parameters. Findings which differed from reference range and were considered clinically significant were to be reported.

Time frame:
first and last visit conducted up to approximately 25 weeks apart
Reported as:
Count of participants · Participants
Investigation of Hematology Parameters
Participants1h Incubation BF-200 ALA3h Incubation BF-200 ALAVehicle (1h and 3h Incubation Pooled)
Screening000
8 weeks post PDT-3000
Other pre-specifiedInvestigation of Urinalysis Parameters

Number of patients with changes in urinalysis parameters. Findings which differed from reference range and were considered clinically significant were to be reported.

Time frame:
first and last visit conducted up to approximately 25 weeks apart
Reported as:
Count of participants · Participants
Investigation of Urinalysis Parameters
Participants1h Incubation BF-200 ALA3h Incubation BF-200 ALAVehicle (1h and 3h Incubation Pooled)
Screening000
8 weeks post PDT-3000
Other pre-specifiedPhysical Examination of Head, Neck, Skin, Lymph Nodes, Thorax Including Heart and Lungs, Abdomen, and Musculoskeletal, Peripheral Vascular and Nervous System Status

Physical examination of head, neck, skin, lymph nodes, thorax including heart and lungs, abdomen, and musculoskeletal, peripheral vascular and nervous system status were to be performed. Abnormal findings considered clinically significant were to be reported.

Time frame:
first and last visit conducted up to approximately 25 weeks apart
Reported as:
Count of participants · Participants
Physical Examination of Head, Neck, Skin, Lymph Nodes, Thorax Including Heart and Lungs, Abdomen, and Musculoskeletal, Peripheral Vascular and Nervous System Status
Participants1h Incubation BF-200 ALA3h Incubation BF-200 ALAVehicle (1h and 3h Incubation Pooled)
Screening — No clinically significant physical examination findings reported403541
Screening — Clinically significant physical examination findings reported201
8 weeks post PDT-3 — No clinically significant physical examination findings reported292129
8 weeks post PDT-3 — Clinically significant physical examination findings reported000
SecondaryPercentage Change in the Number of Nodules & Cysts

The number of nodules and cysts was assessed by investigator. Percentage change from baseline was calculated only for participants whose number of nodules and cysts had changed at 8 weeks after the last PDT.

Time frame:
8 weeks after the last PDT
Reported as:
Mean · percentage
Percentage Change in the Number of Nodules & Cysts
percentage1h Incubation BF-200 ALA3h Incubation BF-200 ALAVehicle (1h and 3h Incubation Pooled)
Nodules-69.39 ± 74.88-16.67 ± 98.32-80.95 ± 37.80
Cysts-6.25 ± 141.97-100.00 ± 0-100.00 ± 0
SecondaryTreatment Success Defined by a Minimum Improvement of the IGA by at Least 2.

Treatment success is defined as a minimum improvement of the IGA score by at least 2 (from baseline (Visit 2) as assessed by investigator).

Time frame:
8 weeks after the last PDT
Reported as:
Count of participants · Participants
Treatment Success Defined by a Minimum Improvement of the IGA by at Least 2.
Participants1h Incubation BF-200 ALA3h Incubation BF-200 ALAVehicle (1h and 3h Incubation Pooled)
Treatment Success Defined by a Minimum Improvement of the IGA by at Least 2.567
SecondaryImprovement of the IGA.

As assessed by the investigator.

Time frame:
8 weeks after the last PDT
Reported as:
Count of participants · Participants
Improvement of the IGA.
Participants1h Incubation BF-200 ALA3h Incubation BF-200 ALAVehicle (1h and 3h Incubation Pooled)
Improvement of the IGA.151320
SecondaryImprovement of the mIGA.

As assessed by the investigator.

Time frame:
8 weeks after the last PDT
Reported as:
Count of participants · Participants
Improvement of the mIGA.
Participants1h Incubation BF-200 ALA3h Incubation BF-200 ALAVehicle (1h and 3h Incubation Pooled)
Improvement of the mIGA.242125
SecondaryImprovement of Scar Severity and Overall Esthetic Appearance.

Improvement of scar severity: As assessed by the investigator via a physical global scale for acne scars (PGA). Overall esthetic appearance: As assessed by the investigator using a 4-point scale (0= very good, 1 = good, 2 = satisfactory, 3 = unsatisfactory)

Time frame:
8 weeks after last PDT
Reported as:
Count of participants · Participants
Improvement of Scar Severity and Overall Esthetic Appearance.
Participants1h Incubation BF-200 ALA3h Incubation BF-200 ALAVehicle (1h and 3h Incubation Pooled)
Acne Scarring Improved6410
Esthetic Appearance, 0=Very good135
Esthetic Appearance, 1=Good10910
Esthetic Appearance, 2=Satisfactory13712
Esthetic Appearance, 3=Unsatisfactory422
SecondarySatisfaction Regarding Esthetic Outcome and Treatment.

As reported by the subject. Subject's Satisfaction with PDT (No = No, I would not choose this treatment again; Yes = Yes, I would choose this treatment again) Assessment of Esthetic Outcome (0=Very good, 1=Good, 2=Satisfactory, 3=Unsatisfactory)

Time frame:
8 weeks after the last PDT.
Reported as:
Count of participants · Participants
Satisfaction Regarding Esthetic Outcome and Treatment.
Participants1h Incubation BF-200 ALA3h Incubation BF-200 ALAVehicle (1h and 3h Incubation Pooled)
Subject's Satisfaction with PDT, No832
Subject's Satisfaction with PDT, Yes211826
Assessment of Esthetic Outcome, 0=Very good7810
Assessment of Esthetic Outcome, 1=Good12711
Assessment of Esthetic Outcome, 2=Satisfactory534
Assessment of Esthetic Outcome, 3=Unsatisfactory533

Adverse events

Collected over Collection of AEs starts with signing the informed consent documents until the final visit (up to 27 weeks).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
1h Incubation BF-200 ALA0/42 (0%)0/42 (0%)40/42 (95.2%)
3h Incubation BF-200 ALA0/36 (0%)1/36 (2.8%)35/36 (97.2%)
Vehicle (1h and 3h Incubation Pooled)0/42 (0%)1/42 (2.4%)31/42 (73.8%)
Most frequent serious events
Most frequent serious events
Event1h Incubation BF-200 ALA3h Incubation BF-200 ALAVehicle (1h and 3h Incubation Pooled)
AppendicitisInfections and infestations0/421/360/42
ManiaPsychiatric disorders0/420/361/42
Most frequent other events
Showing 10 of 14
Most frequent other events
Event1h Incubation BF-200 ALA3h Incubation BF-200 ALAVehicle (1h and 3h Incubation Pooled)
Application site painGeneral disorders35/4234/3617/42
Application site pruritusGeneral disorders35/4230/3613/42
Application site erythemaGeneral disorders15/4214/3611/42
Application site exfoliationGeneral disorders8/428/364/42
Application site oedemaGeneral disorders3/428/363/42
Application site drynessGeneral disorders7/423/362/42
Application site paraesthesiaGeneral disorders6/422/363/42
Application site warmthGeneral disorders5/421/364/42
AcneSkin and subcutaneous tissue disorders2/423/365/42
Application site discolourationGeneral disorders0/423/361/42

Baseline characteristics

Age, Customized
Age, Customized(Participants)1h Incubation BF-200 ALA3h Incubation BF-200 ALA1h Incubation Vehicle3h Incubation VehicleTotal
16-177132729
>=18 years3523191491
Sex: Female, Male
Sex: Female, Male(Participants)1h Incubation BF-200 ALA3h Incubation BF-200 ALA1h Incubation Vehicle3h Incubation VehicleTotal
Female2422141373
Male18147847
Race (NIH/OMB)
Race (NIH/OMB)(Participants)1h Incubation BF-200 ALA3h Incubation BF-200 ALA1h Incubation Vehicle3h Incubation VehicleTotal
American Indian or Alaska Native10001
Asian134210
Native Hawaiian or Other Pacific Islander00000
Black or African American762419
White3125141484
More than one race20013
Unknown or Not Reported02103
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)1h Incubation BF-200 ALA3h Incubation BF-200 ALA1h Incubation Vehicle3h Incubation VehicleTotal
Hispanic or Latino764118
Not Hispanic or Latino35291720101
Unknown or Not Reported01001
Fitzpatrick Skin Type Category
Fitzpatrick Skin Type Category(Participants)1h Incubation BF-200 ALA3h Incubation BF-200 ALA1h Incubation Vehicle3h Incubation VehicleTotal
Type I - III242191468
IV-VI181512752
08

Study locations

9 sites
  • First OC Dermatology
    Fountain Valley, California 92708, United States
  • Cosmetic Laser Dermatology
    San Diego, California 92121, United States
  • Dermatology Associates PA of the Palm Beaches
    Delray Beach, Florida 33445, United States
  • ForCare Clinical Research
    Tampa, Florida 17033, United States
  • DelRicht Research
    Baton Rouge, Louisiana 70809, United States
  • Skin Search of Rochester, Inc
    Rochester, New York 14623, United States
  • Clinical Research Center of the Carolinas
    Charleston, South Carolina 29407, United States
  • DermResearch PA
    Austin, Texas 78759, United States
  • Austin Institute for Clinical Research Inc.
    Pflugerville, Texas 78660, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2021 to primary completion in Aug 2025, 44 months.

Results were first posted in Oct 2026, 1 year 1 month after primary completion.

Of 29 industry-sponsored phase 2 interventional studies under Acne Vulgaris, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 15. This study's 44 months is above that.

Counting every sponsor, half of 37 studies reached it within 9 months; a quarter within 6 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2021
First posted
Oct 18, 2021
StartActual
Dec 10, 2021
Primary completionActual
Aug 22, 2025
CompletionActual
Jan 7, 2026
Results first posted
Oct 1, 2026
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 1, 2026
Primary outcomes
2 edited
What changed in the outcomes
  • EditedRelative changeChange in the numberNumber of inflammatory lesionsInflammatory Lesions (relative change from baselineRelative Change From Baseline) 8 weeks afterWeeks After the lastLast PDT as assessedAssessed by investigatorInvestigator.Time frame: 8 weeks after the last PDT
  • EditedTreatment success definedSuccess Defined by a minimum improvementMinimum Improvement of the modified investigator global assessmentModified Investigator Global Assessment (mIGA) scoreScore by at leastLeast 2 assessedAssessed 8 weeks afterWeeks After the lastLast PDT and resultingResulting in an mIGA scoreScore of 0 (clearClear) or 1 (almost clearAlmost Clear).Time frame: 8 weeks after the last PDT
Oct 1, 2026
Documents
Secondary outcomes
19 edited, 6 added
What changed in the outcomes
  • EditedAbsolute and/or percentage change from baselineChange From Baseline in the numberNumber of lesionsLesions as assessedAssessed by investigatorInvestigator (After the Last PDT).Time frame: 4 or 8 weeks after the last PDT
  • EditedAbsolute and percentage change from baselinePercentage Change From Baseline in the numberNumber of lesionsLesions as assessedAssessed by investigatorInvestigator (After the Last PDT).Time frame: 4 or 8 weeks after the last PDT
  • EditedAbsolute and percentage change from baselineChange From Baseline in the numberNumber of lesionsLesions as assessedAssessed by investigator, only for responders at Visit 3 / 4 weeks afterInvestigator (After Each PDT-1).Time frame: 4 or 8 weeks after PDT-1 → 4 or 8 weeks after the last PDT
  • EditedAbsolute and percentage change from baselinePercentage Change From Baseline in the numberNumber of lesionsLesions as assessedAssessed by investigator, only for responders at Visit 4b / 4 weeks afterInvestigator (After Each PDT-2).Time frame: 4 or 8 weeks after PDT-2 → 4 or 8 weeks after the last PDT
  • EditedAbsolute and percentage changeChange From Baseline in the numberNumber of lesionsLesions as assessedAssessed by investigatorInvestigator, onlyOnly for respondersResponders at Visit 5b3 / 4 weeks afterWeeks After PDT-31.Time frame: 4 or 8 weeks after PDT-3 → 4 or 8 weeks after PDT-1
  • EditedAbsolute Change in the numberNumber of nodulesNodules & cystsCystsTime frame: 8 weeks after the last PDT
  • EditedTreatment success definedSuccess Defined by a minimum improvementMinimum Improvement of the IGA by at leastLeast 2.Time frame: 8 weeks after the last PDT
  • EditedImprovement of scar severityScar Severity and overall esthetic appearanceOverall Esthetic Appearance.Time frame: 8 weeks after last PDT
  • EditedSatisfaction regarding esthetic outcomeRegarding Esthetic Outcome and treatmentTreatment.Time frame: 8 weeks after the last PDT.
  • AddedPercentage Change From Baseline in the Number of Lesions as Assessed by Investigator, Only for Responders at Visit 3 / 4 Weeks After PDT-1.Time frame: 4 or 8 weeks after PDT-1
  • AddedAbsolute Change From Baseline in the Number of Lesions as Assessed by Investigator, Only for Responders at Visit 4b / 4 Weeks After PDT-2.Time frame: 4 or 8 weeks after PDT-2
  • AddedPercentage Change From Baseline in the Number of Lesions as Assessed by Investigator, Only for Responders at Visit 4b / 4 Weeks After PDT-2.Time frame: 4 or 8 weeks after PDT-2
  • AddedAbsolute Change in the Number of Lesions as Assessed by Investigator, Only for Responders at Visit 5b / 4 Weeks After PDT-3.Time frame: 4 or 8 weeks after PDT-3
  • AddedPercentage Change in the Number of Lesions as Assessed by Investigator, Only for Responders at Visit 5b / 4 Weeks After PDT-3.Time frame: 4 or 8 weeks after PDT-3
  • AddedPercentage Change in the Number of Nodules & CystsTime frame: 8 weeks after the last PDT
  • Editedother outcomeFrequency and severitySeverity of adverse eventsAdverse Events (AEs), seriousSerious AEs (SAEs), AEs of special interestSpecial Interest (AESI) and treatmentTreatment-emerged adverse eventsAdverse Events (TEAEs).Time frame: from screening to study completion, over a duration of up to approximately 25 weeks
  • Editedother outcomeApplication site skin reactions assessedSite Skin Reaction Assessed by the investigator.InvestigatorTime frame: from screening to study completion, over a duration of up to approximately 25 weeks → During illumination (10 minutes) at PDT-1, PDT-2, and PDT-3
  • Editedother outcomeApplication site discomfort reportedSite Discomfort Reported by the subjectsSubjects.Time frame: from screening to study completion, over a duration of up to approximately 25 weeks → During illumination (10 minutes) at PDT-1, PDT-2, and PDT-3
  • Editedother outcomePain during illumination reportedDuring Illumination Reported by the subjectSubject.Time frame: from screening to study completion, over a duration of up to approximately 25 weeks → During illumination (10 minutes) at PDT-1, PDT-2, and PDT-3
  • Editedother outcomeChanges in blood pressureBlood PressureTime frame: at all clinic visits conducted over a duration of approximately 25 weeks
  • Editedother outcomeChanges in heart rateHeart RateTime frame: at all clinic visits conducted over a duration of approximately 25 weeks
  • Editedother outcomeInvestigation of clinical chemistry parametersClinical Chemistry ParametersTime frame: first and last visit conducted up to approximately 25 weeks apart
  • Editedother outcomeInvestigation of hematology parametersHematology ParametersTime frame: first and last visit conducted up to approximately 25 weeks apart
  • Editedother outcomeInvestigation of urinalysis parametersUrinalysis ParametersTime frame: first and last visit conducted up to approximately 25 weeks apart
  • Editedother outcomePhysical examinationExamination of headHead, neckNeck, skinSkin, lymph nodesLymph Nodes, thorax including heartThorax Including Heart and lungsLungs, abdomenAbdomen, and musculoskeletalMusculoskeletal, peripheral vascularPeripheral Vascular and nervous system statusNervous System StatusTime frame: first and last visit conducted up to approximately 25 weeks apart
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    Results posted
    Primary outcomes 2 edited
    What changed in the outcomes
    • EditedRelative changeChange in the numberNumber of inflammatory lesionsInflammatory Lesions (relative change from baselineRelative Change From Baseline) 8 weeks afterWeeks After the lastLast PDT as assessedAssessed by investigatorInvestigator.Time frame: 8 weeks after the last PDT
    • EditedTreatment success definedSuccess Defined by a minimum improvementMinimum Improvement of the modified investigator global assessmentModified Investigator Global Assessment (mIGA) scoreScore by at leastLeast 2 assessedAssessed 8 weeks afterWeeks After the lastLast PDT and resultingResulting in an mIGA scoreScore of 0 (clearClear) or 1 (almost clearAlmost Clear).Time frame: 8 weeks after the last PDT
    Secondary outcomes 19 edited, 6 added
    What changed in the outcomes
    • EditedAbsolute and/or percentage change from baselineChange From Baseline in the numberNumber of lesionsLesions as assessedAssessed by investigatorInvestigator (After the Last PDT).Time frame: 4 or 8 weeks after the last PDT
    • EditedAbsolute and percentage change from baselinePercentage Change From Baseline in the numberNumber of lesionsLesions as assessedAssessed by investigatorInvestigator (After the Last PDT).Time frame: 4 or 8 weeks after the last PDT
    • EditedAbsolute and percentage change from baselineChange From Baseline in the numberNumber of lesionsLesions as assessedAssessed by investigator, only for responders at Visit 3 / 4 weeks afterInvestigator (After Each PDT-1).Time frame: 4 or 8 weeks after PDT-1 → 4 or 8 weeks after the last PDT
    • EditedAbsolute and percentage change from baselinePercentage Change From Baseline in the numberNumber of lesionsLesions as assessedAssessed by investigator, only for responders at Visit 4b / 4 weeks afterInvestigator (After Each PDT-2).Time frame: 4 or 8 weeks after PDT-2 → 4 or 8 weeks after the last PDT
    • EditedAbsolute and percentage changeChange From Baseline in the numberNumber of lesionsLesions as assessedAssessed by investigatorInvestigator, onlyOnly for respondersResponders at Visit 5b3 / 4 weeks afterWeeks After PDT-31.Time frame: 4 or 8 weeks after PDT-3 → 4 or 8 weeks after PDT-1
    • EditedAbsolute Change in the numberNumber of nodulesNodules & cystsCystsTime frame: 8 weeks after the last PDT
    • EditedTreatment success definedSuccess Defined by a minimum improvementMinimum Improvement of the IGA by at leastLeast 2.Time frame: 8 weeks after the last PDT
    • EditedImprovement of scar severityScar Severity and overall esthetic appearanceOverall Esthetic Appearance.Time frame: 8 weeks after last PDT
    • EditedSatisfaction regarding esthetic outcomeRegarding Esthetic Outcome and treatmentTreatment.Time frame: 8 weeks after the last PDT.
    • AddedPercentage Change From Baseline in the Number of Lesions as Assessed by Investigator, Only for Responders at Visit 3 / 4 Weeks After PDT-1.Time frame: 4 or 8 weeks after PDT-1
    • AddedAbsolute Change From Baseline in the Number of Lesions as Assessed by Investigator, Only for Responders at Visit 4b / 4 Weeks After PDT-2.Time frame: 4 or 8 weeks after PDT-2
    • AddedPercentage Change From Baseline in the Number of Lesions as Assessed by Investigator, Only for Responders at Visit 4b / 4 Weeks After PDT-2.Time frame: 4 or 8 weeks after PDT-2
    • AddedAbsolute Change in the Number of Lesions as Assessed by Investigator, Only for Responders at Visit 5b / 4 Weeks After PDT-3.Time frame: 4 or 8 weeks after PDT-3
    • AddedPercentage Change in the Number of Lesions as Assessed by Investigator, Only for Responders at Visit 5b / 4 Weeks After PDT-3.Time frame: 4 or 8 weeks after PDT-3
    • AddedPercentage Change in the Number of Nodules & CystsTime frame: 8 weeks after the last PDT
    • Editedother outcomeFrequency and severitySeverity of adverse eventsAdverse Events (AEs), seriousSerious AEs (SAEs), AEs of special interestSpecial Interest (AESI) and treatmentTreatment-emerged adverse eventsAdverse Events (TEAEs).Time frame: from screening to study completion, over a duration of up to approximately 25 weeks
    • Editedother outcomeApplication site skin reactions assessedSite Skin Reaction Assessed by the investigator.InvestigatorTime frame: from screening to study completion, over a duration of up to approximately 25 weeks → During illumination (10 minutes) at PDT-1, PDT-2, and PDT-3
    • Editedother outcomeApplication site discomfort reportedSite Discomfort Reported by the subjectsSubjects.Time frame: from screening to study completion, over a duration of up to approximately 25 weeks → During illumination (10 minutes) at PDT-1, PDT-2, and PDT-3
    • Editedother outcomePain during illumination reportedDuring Illumination Reported by the subjectSubject.Time frame: from screening to study completion, over a duration of up to approximately 25 weeks → During illumination (10 minutes) at PDT-1, PDT-2, and PDT-3
    • Editedother outcomeChanges in blood pressureBlood PressureTime frame: at all clinic visits conducted over a duration of approximately 25 weeks
    • Editedother outcomeChanges in heart rateHeart RateTime frame: at all clinic visits conducted over a duration of approximately 25 weeks
    • Editedother outcomeInvestigation of clinical chemistry parametersClinical Chemistry ParametersTime frame: first and last visit conducted up to approximately 25 weeks apart
    • Editedother outcomeInvestigation of hematology parametersHematology ParametersTime frame: first and last visit conducted up to approximately 25 weeks apart
    • Editedother outcomeInvestigation of urinalysis parametersUrinalysis ParametersTime frame: first and last visit conducted up to approximately 25 weeks apart
    • Editedother outcomePhysical examinationExamination of headHead, neckNeck, skinSkin, lymph nodesLymph Nodes, thorax including heartThorax Including Heart and lungsLungs, abdomenAbdomen, and musculoskeletalMusculoskeletal, peripheral vascularPeripheral Vascular and nervous system statusNervous System StatusTime frame: first and last visit conducted up to approximately 25 weeks apart
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05080764
Lead sponsor
Biofrontera Inc.
Responsible party
Sponsor
First posted
Oct 18, 2021
Start date
Dec 10, 2021
Primary completion
Aug 22, 2025
Completion
Jan 7, 2026
Results posted
Oct 1, 2026
Last update
Oct 1, 2026

Study contacts

Mitchel P Goldman, MD
principal investigator · Dermatology Cosmetic Laser Medical Associates of La Jolla, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion